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An increase in the prevalence of obesity and the metabolic
syndrome as a result of changes in eating habits, both quanti-
tative (over-eating) and qualitative (e.g. high fructose con-
sumption), and a lack of exercise contribute to fatty liver dis-
ease. Non-alcoholic fatty liver disease (NAFLD) is a clinical
histological spectrum ranging from steatosis to non-alcoholic
steatohepatitis (NASH) and affects more than 30% of the gen-
eral population [1].
The European Association for the Study of the Liver
(EASL), the European Association for the Study of Diabetes
(EASD) and the European Association for the Study of
Obesity (EASO) have recently published the first comprehen-
sive joint evidence-based Clinical Practice Guidelines for the
management of NAFLD [2].
While reading these important guidelines two critical ques-
tions emerge: (1) is this an algorithm that is likely to be follow-
ed in routine care, and (2) what are the health economic im-
plications and therefore what is the likelihood of these guide-
lines being implemented by healthcare systems?
While previous guidelines have suggested similar algo-
rithms (for examples see [3, 4]), a recently published survey
by Rinella et al indicates that only a minority of gastroenter-
ologists follow them. Less than 25% of the participating spe-
cialists have performed liver biopsies for the diagnosis for
NASH when indicated [5], leaving NASH under-diagnosed
even in gastroenterology and hepatology clinics. Thus, while
the guidelines are clear and evidence based, the clinical reality
remains sobering.
If the resources needed are weighed up against the clinical
relevance of the findings in terms of treatment decision mak-
ing, it is questionable whether liver biopsies should be per-
formed on a large scale to differentiate steatosis from NASH.
As long as the major treatment option for both conditions is
lifestyle intervention including diet and exercise, with limited
evidence for pharmacological treatment, discussions about the
indications for biopsy-based differential diagnosis, risk of the
intervention and the possible financial implications will and
have to continue. Despite the fact that no drug has been ap-
proved for the indication of NASH, and guidelines recom-
mend that pharmacological treatment should be reserved for
those with biopsy-proven NASH, particularly those with
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significant fibrosis, in reality, treatment initiation is often sole-
ly based on clinical judgement without biopsy [5]. This obser-
vation again highlights the urgent need for reliable non-
invasive biomarkers and imaging tools to differentiate
NASH from steatosis, which would allow broader acceptance
and more targeted treatment.
However, even if evidence-based and approved pharmaco-
logical treatment was available, it is questionable to what ex-
tent local health budgets may be able to offer it to the individ-
ual patient. This raises the additional importance of population
strategies. Obesity has been developing to a central disease for
many diseases, a gateway for ill health [6]. Given that the
obesity epidemic is undoubtedly the strongest contributor to
the burden of fatty liver disease in the 21st century, the EASO
has announced the Milan Declaration 2015 [7]. This calls for
action on obesity, which has emerged as the most prominent
single disease of our time, hepatic steatosis being one of the
consequences in many patients. Societal changes are called
upon which might help the individual patient, too, such that
the gap between what we can afford on an individual level and
the needs of the population as a whole could be bridged. We
think such population strategies should be mandatory
everywhere.
In the meantime the present Clinical Practice Guidelines
provide the best available evidence and should be followed
to provide the best possible treatment for our patients.
However, assessment of how the guidelines are translated into
clinical practice in Europe and what the particular limitations
are, is critical in order to address these issues in future updates.
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